Unknown PHASE1 INTERVENTIONAL 1-arm NCT03634982

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors

Sponsor: Revolution Medicines, Inc.

Conditions Solid Tumors

Interventions RMC-4630

Updated 21 times since 2018 Last updated: Aug 31, 2022 Started: Sep 28, 2018 Primary completion: Mar 31, 2023 Completion: May 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03634982, this PHASE1 trial focuses on Solid Tumors and remains ongoing. Sponsored by Revolution Medicines, Inc., it has been updated 21 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

21 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Oct 2023 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Active Not Recruiting → Unknown Status
Sep 2022 — Oct 2023 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Feb 2022 — Sep 2022 [monthly]

Recruiting PHASE1

▶ Show 16 earlier versions

Sep 2021 — Feb 2022 [monthly]

Recruiting PHASE1
May 2021 — Sep 2021 [monthly]

Recruiting PHASE1
Jan 2021 — May 2021 [monthly]

Recruiting PHASE1
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Sep 2020 — Nov 2020 [monthly]

Recruiting PHASE1
Jul 2020 — Sep 2020 [monthly]

Recruiting PHASE1
Oct 2019 — Jul 2020 [monthly]

Recruiting PHASE1
Aug 2019 — Oct 2019 [monthly]

Recruiting PHASE1
Jun 2019 — Aug 2019 [monthly]

Recruiting PHASE1
May 2019 — Jun 2019 [monthly]

Recruiting PHASE1
Apr 2019 — May 2019 [monthly]

Recruiting PHASE1
Jan 2019 — Apr 2019 [monthly]

Recruiting PHASE1
Dec 2018 — Jan 2019 [monthly]

Recruiting PHASE1
Nov 2018 — Dec 2018 [monthly]

Recruiting PHASE1
Oct 2018 — Nov 2018 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2018 — Oct 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Revolution Medicines, Inc.
Sanofi

Data source: Revolution Medicines, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Austin, United States , Boston, United States , Duarte, United States , Nashville, United States , Oklahoma City, United States , Orange, United States , Sacramento, United States , San Francisco, United States , Sarasota, United States and 2 more locations